Puma Biotechnology (PBYI) Other Non Operating Income (2011 - 2026)
Puma Biotechnology (PBYI) posted Other Non Operating Income of $130000.0 for Q1 2026, up 118.81% on a QoQ basis from -$691000.0 in Q4 2025, and down 63.79% year-over-year from $359000.0 in Q1 2025.
Puma Biotechnology (PBYI) Other Non Operating Income (2011 - 2026) Analysis & Trends
Puma Biotechnology's Other Non Operating Income history runs 15 years deep, the most recent figure standing at $130000.0 for Q1 2026.
- Quarterly Other Non Operating Income fell 63.79% year-over-year to $130000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$36000.0 (down 103.19% YoY) and the FY2025 annual result came in at $193000.0, down 77.61% from the prior year.
- Other Non Operating Income was $130000.0 for Q1 2026 at Puma Biotechnology, up from -$691000.0 in the prior quarter.
- Across five years, Other Non Operating Income topped out at $410000.0 in Q2 2025 and bottomed at -$691000.0 in Q4 2025.
- A 5-year average of $68058.8 and a median of $86000.0 in 2023 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income soared 368.92% — and 2025, when it sank 357.84%.
- Puma Biotechnology's Other Non Operating Income stood at -$204000.0 in 2022, then surged by 42.16% to -$118000.0 in 2023, then soared by 327.12% to $268000.0 in 2024, then sank by 357.84% to -$691000.0 in 2025, then soared by 118.81% to $130000.0 in 2026.
- Business Quant data shows PBYI's Other Non Operating Income at $130000.0 in Q1 2026, -$691000.0 in Q4 2025, and $115000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Puma Biotechnology | 406.51 Mn | 368.22 Mn | 34.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 130,000.00 |
| Dec 31, 2025 | -691,000.00 |
| Sep 30, 2025 | 115,000.00 |
| Jun 30, 2025 | 410,000.00 |
| Mar 31, 2025 | 359,000.00 |
| Dec 31, 2024 | 268,000.00 |
| Sep 30, 2024 | 347,000.00 |
| Jun 30, 2024 | 156,000.00 |
| Mar 31, 2024 | 91,000.00 |
| Dec 31, 2023 | -118,000.00 |
| Sep 30, 2023 | 74,000.00 |
| Jun 30, 2023 | 86,000.00 |
| Mar 31, 2023 | -42,000.00 |
| Dec 31, 2022 | -204,000.00 |
| Sep 30, 2022 | 64,000.00 |
| Jun 30, 2022 | 62,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Sep 30, 2021 | -8.15 Mn |
| Jun 30, 2021 | 60,000.00 |
| Mar 31, 2021 | 42,000.00 |